PCI Pharma Services Funnels Over $365 Million for Advanced Drug Delivery

PCI Pharma Services, a top CDMO specializing in complex biopharma therapies, is dedicating over $365 million to enhance infrastructure for assembling and packaging drug-device combination products with advanced drug delivery systems, particularly focusing on injectable formats. Consisting of enhanced facilities in Europe and North America, this initiative is a key component of PCI's worldwide investment strategy, backed by new business revenue, and aimed at supporting future expansion.

PCI's investments in biologics leverage over two decades of expertise, solidifying its leadership in the field, notably through its top-tier Biotech Center of Excellence in Philadelphia. That site utilizes precise handling machinery for pre-filled syringes, syringe assembly and labeling, vial labeling and cartoning, and autoinjector assembly. Recently, PCI made significant investments in cutting-edge, automated advanced drug delivery technologies to improve capabilities and capacities at this facility, ensuring it stays ahead in innovation.

Together, the new initiatives enhance PCI's capability to oversee the entire life cycle of these products, from developing and producing sterile drugs to supplying clinical trials, launching products, and commercializing them.

In Rockford, Illinois, PCI in the US has ambitious plans for a 545,000-square-foot expansion on its campus, focused on advanced drug delivery and drug-device combination assembly and packaging. Emphasizing the step-by-step approach is a large project spanning 475,000 square feet, with 345,000 dedicated to advanced drug delivery injectable packaging and 130,000 allocated for extra warehousing of products at various development stages.